Lineage Cell Therapeutics (LCTX) Revenue (2010 - 2026)
Lineage Cell Therapeutics posted quarterly Revenue of $1.7 million for Q1 2026, up 14.85% year-on-year from $1.5 million in Q1 2025, and down 73.9% on a QoQ basis from $6.6 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) has 17 years of Revenue data on file, last reported at $1.7 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue rose 14.85% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $14.8 million (up 54.64% YoY), and the FY2025 full-year result was $14.6 million, up 53.24% from the prior year.
- Revenue for Q1 2026 stood at $1.7 million, down from $6.6 million in the prior quarter.
- Across five years, Revenue topped out at $6.6 million in Q4 2025 and bottomed at $1.2 million in Q3 2023.
- The 5-year median for Revenue is $2.8 million (2025), against an average of $2.9 million.
- Peak annual rise in Revenue reached 1239.39% in 2022, while the deepest fall reached 96.17% in 2022.
- A 5-year view of Revenue shows it stood at $1.9 million in 2022, then rose by 9.03% to $2.1 million in 2023, then soared by 37.36% to $2.9 million in 2024, then jumped by 130.4% to $6.6 million in 2025, then sank by 73.9% to $1.7 million in 2026.
- The last three Revenue figures came in at $1.7 million (Q1 2026), $6.6 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Lineage Cell Therapeutics | 325.89 Mn | 261.99 Mn | 1.73 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.73 Mn |
| Dec 31, 2025 | 6.61 Mn |
| Sep 30, 2025 | 3.68 Mn |
| Jun 30, 2025 | 2.77 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 2.87 Mn |
| Sep 30, 2024 | 3.78 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 3.23 Mn |
| Mar 31, 2023 | 2.39 Mn |
| Dec 31, 2022 | 1.92 Mn |
| Sep 30, 2022 | 3.00 Mn |
| Jun 30, 2022 | 4.55 Mn |
| Mar 31, 2022 | 5.24 Mn |
| Dec 31, 2021 | 50.00 Mn |
| Sep 30, 2021 | 2.27 Mn |
| Jun 30, 2021 | 512,000.00 |
| Mar 31, 2021 | 391,000.00 |
| Dec 31, 2020 | 355,000.00 |
| Sep 30, 2020 | 571,000.00 |
| Jun 30, 2020 | 386,000.00 |
| Mar 31, 2020 | 514,000.00 |
| Dec 31, 2019 | 1.24 Mn |
| Sep 30, 2019 | 567,000.00 |
| Jun 30, 2019 | 779,000.00 |
| Mar 31, 2019 | 928,000.00 |
| Dec 31, 2018 | 758,000.00 |
| Sep 30, 2018 | 982,000.00 |
| Jun 30, 2018 | 2.55 Mn |
| Mar 31, 2018 | 701,000.00 |
| Dec 31, 2017 | 945,000.00 |
| Sep 30, 2017 | 1.64 Mn |
| Jun 30, 2017 | 376,000.00 |
| Mar 31, 2017 | 333,000.00 |
| Dec 31, 2016 | 1.10 Mn |
| Sep 30, 2016 | 1.44 Mn |
| Jun 30, 2016 | 1.17 Mn |
| Mar 31, 2016 | 1.85 Mn |
| Dec 31, 2015 | 1.31 Mn |
| Sep 30, 2015 | 1.87 Mn |
| Jun 30, 2015 | 1.75 Mn |
| Mar 31, 2015 | 1.00 Mn |
| Dec 31, 2014 | 1.67 Mn |
| Sep 30, 2014 | 960,000.00 |
| Jun 30, 2014 | 855,000.00 |
| Mar 31, 2014 | 935,000.00 |
| Dec 31, 2013 | 1.67 Mn |
| Sep 30, 2013 | 507,384.00 |
| Jun 30, 2013 | 1.04 Mn |
| Mar 31, 2013 | 431,724.00 |
| Dec 31, 2012 | 1.07 Mn |
| Sep 30, 2012 | 833,817.00 |
| Jun 30, 2012 | 949,746.00 |
| Mar 31, 2012 | 631,946.00 |
| Dec 31, 2011 | 1.63 Mn |
| Sep 30, 2011 | 1.14 Mn |
| Jun 30, 2011 | 755,553.00 |
| Mar 31, 2011 | 824,629.00 |
| Dec 31, 2010 | 1.13 Mn |
| Sep 30, 2010 | 108,523.00 |